Kuwait Medical Electronic Library

Possible Lurasidone-Associated Dose-Dependent QTc Prolongation in First-Episode Psychosis

Ahmed Naguy 1, Suliman Al-Khadhari 1, Saxby Pridmore 1

Affiliations

expand

27 June 2022

Abstract

This case is one of the earliest to report on lurasidone-related QTc prolongation in a dose-dependent fashion in CAP population at therapeutic doses. Although these reports remain scarce, it behoves prescribers to be vigilant and mindful of these unusual but serious side effects especially in setting of cumulative risks.

Keywords: FEP; QTc; adolescent; lurasidone.

Figures

Figure 1 ECG with Lurasidone at 80 mg/d and Presyncope. (Courtesy of Dr Naguy, 2022)

Similar articles

Antipsychotics and risk of QT prolongation: a pharmacovigilance study.

Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, Montastruc F.Psychopharmacology (Berl). 2023 Jan;240(1):199-202. doi: 10.1007/s00213-022-06293-4. Epub 2022 Dec 14.PMID: 36515735

Lurasidone-Associated Neuroleptic Malignant Syndrome.

Lee M, Marshall D, Saddichha S.J Clin Psychopharmacol. 2017 Oct;37(5):639-640. doi: 10.1097/JCP.0000000000000774.PMID: 28806387 No abstract available.

Lurasidone in first-episode psychosis with predominant depressive symptoms: a case report.

Ricci V, Di Salvo G, Maina G.Int Clin Psychopharmacol. 2023 Jul 1;38(4):275-280. doi: 10.1097/YIC.0000000000000465. Epub 2023 Feb 27.PMID: 36853746

[Antipsychotic pharmacotherapy for delirious syndromes - only temporary, symptom-oriented and considering QTc time].

Schwerthöffer D, Förstl H, Fatke B.MMW Fortschr Med. 2019 Jul;161(Suppl 5):1-6. doi: 10.1007/s15006-019-0743-x. Epub 2019 Jul 16.PMID: 31313266 Review. German.

Lurasidone: a clinical overview.

Kane JM.J Clin Psychiatry. 2011;72 Suppl 1:24-8. doi: 10.4088/JCP.10075su1.05.PMID: 22217440 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/